The effect of different anti-inflammatory treatment strategies on process of atherosclerosis in ankylosing spondylitis patients

被引:0
|
作者
Bozdayi, Mehmet Akif [1 ]
Ulusal, Hasan [2 ]
Turan, Neytullah [3 ]
Altindag, Ozlem [3 ]
Orkmez, Mustafa [2 ]
Taysi, Seyithan [2 ]
Tarakcioglu, Mehmet [2 ]
机构
[1] Gaziantep Univ, Fac Med, Dept Med Biochem, TR-27310 Gaziantep, Turkiye
[2] Gaziantep Univ, Dept Med Biochem, Gaziantep, Turkiye
[3] Gaziantep Univ, Dept Phys Med & Rehabil, Gaziantep, Turkiye
来源
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI | 2023年 / 48卷 / 02期
关键词
ankylosing spondylitis; anti-TNF alpha; atherosclerosis; inflammation; oxidative stress; INTIMA-MEDIA THICKNESS; SUBCLINICAL ATHEROSCLEROSIS; THIOL/DISULFIDE HOMEOSTASIS; ARTERIAL STIFFNESS; DISEASE-ACTIVITY; SPONDYLARTHROPATHIES; INFLAMMATION; PREVALENCE; MARKERS; INDEX;
D O I
10.1515/tjb-2022-0169
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Objectives: Our aim in this study was to examine the effects of different anti-inflammatory treatment strategies on the process of atherosclerosis, which is an important cause of mortality in ankylosing spondylitis (AS) patients, by examining the possible effect of treatments on inflammation, lipid profile and oxidative stress parameters in patients with AS.Methods: In this study, 32 healthy volunteers served as the control group in addition to a total of 76 AS patients who were divided into two groups according to whether they were receiving anti-TNF medications or not. We assessed the levels of inflammation, oxidative stress, lipid profile pa-rameters, and oxidized low-density lipoprotein (oxLDL). The atherogenic index of plasma (AIP), non-HDL cholesterol levels, BASDAI, and BASFI scores were also calculated.Results: AS patient groups and the control group had similar lipid profile parameters, thiol-disulfide homeostasis metrics, non-HDL cholesterol, oxLDL, and AIP levels (p > 0.05). In contrast to AS patients receiving non-anti-TNF treatment, the BASDAI and BASFI scores, ESR, and CRP levels were lower in AS patients receiving anti-TNF treatment (p < 0.05). In contrast to the controls, AS patients demonstrated high TOS and OSI values (p < 0.05).Conclusions: AS patients face increased oxidative stress that does not correlate with inflammatory status and disease activation level. Anti-TNF alpha treatment may reduce some risk factors of atherosclerotic CVD in AS patients.
引用
收藏
页码:183 / 189
页数:7
相关论文
共 50 条
  • [21] Effects of nonsteroidal anti-inflammatory drugs on serum proinflammatory cytokines in the treatment of ankylosing spondylitis
    Yan, Yong
    Guo, Tuan-Mao
    Zhu, Chao
    BIOCHEMISTRY AND CELL BIOLOGY, 2018, 96 (04) : 450 - 456
  • [22] Emerging anti-inflammatory drugs for atherosclerosis
    Berman, Jeremy P.
    Farkouh, Michael E.
    Rosenson, Robert S.
    EXPERT OPINION ON EMERGING DRUGS, 2013, 18 (02) : 193 - 205
  • [23] Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis
    Kim, Ji-Won
    Yoon, Jun Sik
    Park, Sojeong
    Kim, Hasung
    Kim, Bo young
    Lee, Hwajeong
    Park, Sung-Hoon
    Kim, Seong-Kyu
    Choe, Jung-Yoon
    RHEUMATOLOGY, 2024, 64 (01) : 261 - 267
  • [24] Emerging Anti-inflammatory Therapies for Atherosclerosis
    Roubille, Francois
    Kritikou, Ekaterini A.
    Roubille, Camille
    Tardif, Jean-Claude
    CURRENT PHARMACEUTICAL DESIGN, 2013, 19 (33) : 5840 - 5849
  • [25] Increased PCSK9 associated with cIMT in AS: A useful marker for subclinical atherosclerosis in patients with ankylosing spondylitis
    Karakoyun, Ahmet
    Akkubak, Yasemin
    Goktepe, Mevlut Hakan
    Yilmaz, Pinar Diydem
    Kadiyoran, Cengiz
    Ogul, Mustafa
    Kucuk, Adem
    ARCHIVES OF RHEUMATOLOGY, 2024, 39 (04) : 652 - 661
  • [26] Association of anti-TNF-α treatment with gut microbiota of patients with ankylosing spondylitis
    Dai, Qinghong
    Xia, Xuyang
    He, Chenjia
    Huang, Yupeng
    Chen, Yidan
    Wu, Yang
    Chen, Yuehong
    Hou, Qianqian
    Shu, Yang
    Zhang, Wei
    Xu, Heng
    Yin, Geng
    Xie, Qibing
    PHARMACOGENETICS AND GENOMICS, 2022, 32 (07) : 247 - 256
  • [27] Serum Interleukin-23/17 Levels in Ankylosing Spondylitis Patients Treated with Nonsteroidal Anti-Inflammatory Drugs: A Prospective Cohort Study
    Deveci, Hulya
    Turk, Ayla Cagliyan
    Ozmen, Zeliha Cansel
    Deveci, Koksal
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2019, 39 (09) : 572 - 576
  • [28] Serum interα-trypsin inhibitor heavy chain H4 may be an anti-inflammatory marker reflecting disease risk, activity and treatment outcome of ankylosing spondylitis
    Sun, Zhumin
    Zhang, Yang
    Zhou, Haiyan
    Li, Jingyun
    Zhou, Yue
    Wang, Liyun
    SCANDINAVIAN JOURNAL OF CLINICAL & LABORATORY INVESTIGATION, 2023, 83 (08) : 540 - 547
  • [29] Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study
    Berg, Inger Jorid
    Semb, Anne Grete
    van der Heijde, Desiree
    Kvien, Tore K.
    Hisdal, Jonny
    Olsen, Inge C.
    Dagfinrud, Hanne
    Provan, Sella A.
    SEMINARS IN ARTHRITIS AND RHEUMATISM, 2014, 44 (03) : 309 - 313
  • [30] Gelsolin levels are decreased in ankylosing spondylitis patients undergoing anti-TNF-alpha therapy
    Genre, F.
    Lopez-Mejias, R.
    Miranda-Filloy, J. A.
    Ubilla, B.
    Carnero-Lopez, B.
    Gomez-Acebo, I.
    Blanco, R.
    Ochoa, R.
    Rueda-Gotor, J.
    Gonzalez-Juanatey, C.
    Llorca, J.
    Gonzalez-Gay, M. A.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2014, 32 (02) : 218 - 224